Domino Printing Sciences

Domino Printing Sciences Bar Hill
CB23 8TU
United Kingdom

Tel: +44 (0) 1954 782551
Fax: +44 (0) 1954 782874

Company Overview

Founded in 1978, Domino has a global reputation for the development and manufacture of coding, marking and printing technologies that satisfy the compliance and productivity requirements of manufacturers around the world across every sector. Unrivalled in its commitment to product development, Domino’s portfolio incorporates complete end-to-end coding solutions spanning primary, secondary and tertiary applications.

Innovative ink jet, laser, print & apply and thermal transfer overprinting technologies are deployed for the application of variable data, bar codes and unique traceability codes onto product and packaging across many industrial sectors, including food, beverage, pharmaceutical and industrial products.


In 2013/14 the Domino Group (Domino Printing Sciences plc) achieved a turnover of £350m; it is listed in the FTSE 250 share index on the London Stock Exchange (share code DNO) and was named Company of the Year in the 2010 UK PLC Awards. The Group employs 2,200 people worldwide and sells to more than 120 countries through a global network of 25 subsidiary offices and more than 200 distributors. Domino's manufacturing facilities are situated in China, Germany, India, Sweden, UK and USA.

For further information on Domino, please visit
View our "Innovative coding products & world class service" video here.

Coding and marking for patient safety

In Asia, Europe, South America and the USA, governments are drafting legislation to protect consumer from counterfeit and falsified medicines. The fundamental premise of each is item-level serialisation – assigning a unique identity to each unit of sale. ANVISA in Brazil, ANMAT in Argentina, MHW in South Korea, SFDA in China, the Drug Quality and Security Act in the USA and the EU FMD place new obligations on all branches of the industry – manufacturers, generics producers, contract packers, repackers and importers. All activities related to drug serialisation that are evolving in different countries are backed by the overarching global initiative managed under the auspices of the WHO. Its International Medical Products Anti-Counterfeiting Taskforce (IMPACT) develops principles and elements for national legislation against counterfeit medical products.

Adopted in 2011 and aimed at stemming the flow of falsified medicines reaching the open market within the European Economic area, the EU Falsified Medicines Directive (FMD 2011/62/EU) will within a few years, completely change the landscape of the European pharmaceutical business model. The new obligations on all branches of the industry, with a current deadline of 2018, centres around the unique identification of products at unit of sale level.

"Serialisation implementation is the single greatest challenge the pharmaceutical industry has ever seen, impacting right across the business and supply chain, requiring a complete re-assessment of operations." Craig Stobie Head - Global Life Sciences Team, Domino

Click on the following links to see Ian Haynes, founder and CEO of 3C Innovation Ltd, Grant Courtney, GSK and EFPIA, Mark Davison, Blue Sphere Health Ltd, and Roger Lamb, GS1 UK Healthcare Sector Manager, speak about the EU FMD.

Domino’s Global Life Sciences Group

In 2011 Domino established a Global Life Sciences Group dedicated to helping manufacturers comply with emerging pharmaceutical legislation. The Group consolidates Domino’s industry-leading expertise in pharmaceutical legislative compliance solutions and comprises specialists in all the critical disciplines, including legislative standards, validation of automated manufacturing good practice, code formats and serialisation.

  • Click here to download Domino’s 2013 white paper: "The hidden challenges of serialisation"

  • Click here to view Domino’s 2014 white paper: "Serialisation brings with it the need for aggregation"

Domino’s Partner Programme

Domino’s i-Tech Partner Programme enables Original Equipment Manufacturers (OEMs) and technology partners to demonstrate legislative compliance through compatibility of its products or solutions with the Domino i-Tech portfolio.

Initially aimed at OEMs and integrator operating in the Pharmaceutical sector, the i-Tech Partner Programme is primarily concerned with Domino’s partners’ ability to meet the primary packaging level serialisation and data requirements as set out by emerging legislation such as the EU FMD.

Open to all eligible OEMs and integrators, the programme seeks to share expertise and help manufacturers prepare for, and comply with, the legislative framework of the pharmaceutical sector.

For further information on the i-Tech Partner Programme, click here.
View our "Coding for compliance" video here.

Pharmaceutical Industry Experts

Craig Stobie Head - Global Life Sciences Team, Domino

Stobie has worked for Domino for over 18 years in technical, operations, service and commercial roles. A graduate chemist and physicist with further qualifications in quality and safety assessment, Craig has a broad view of the legislative and commercial pressures facing the healthcare sector.

Craig’s current role involves shaping and leading Domino’s initiatives for the healthcare sector globally. He advises international companies, OEMs, technology providers and legislators on the implementation of 2D coding, serialisation, aggregation, Track & Trace and brand protection projects.

Bart Vansteenkiste EU Life Sciences Sector Manager, Domino

Bart was formerly Pharmaceutical and OEM key account manager for Domino Belgium, before joining the Domino FMD group in 2011. Within this group Bart is focussing on the legislative and technical challenges facing the healthcare sector, and he regularly attends and presents at conferences across Europe on behalf of Domino.

Bart advises Domino’s customers and sales channels on the implications of the legislative requirements and the implementation of 2D coding, serialisation, aggregation and Track & Trace projects. Bart works in close co-operation with a number of leading OEM partners in Germany and Italy and with trade associations like EFPIA and the EGA.

Mark Shaffer Life Sciences Business Development Manager, Domino North America

Mark is responsible for directing Domino’s North American activity in the Life Sciences sector with a primary focus on serialisation and OEM development.

Prior to joining Domino in 2001, Mark’s career began in the printing industry and transitioned into the packaging equipment industry in the mid 1990s. His experience in the packaging industry has created a broad understanding of the critical components required for successful implementation of packaging systems, from design to integration through validation.


Click here to download our latest brochure


Click here to contact your local Domino office or distributor.


Home  |  About us  |  Contact us  |  Advertise  |  Links  |  Partners  |  Privacy Policy  |   |  RSS feed   |  back to top